Statistical issues: a roundtable discussion
Norris E. Alderson, Gregory Campbell, Ralph B. D’Agostino et al. · Clinical Trials · 2005
Dr Alderson: I am Norris Alderson. I am Associate Commissioner for Science at FDA, and I had the privilege of working with a Planning Committee to arrange for this workshop. I was the only non-statistician in the group, I must tell you, and this was really an experience for me. I want to introduce this panel because I think it is unique from the perspective that it has representatives from FDA, industry, and academia. They are Dr Susan Ellenberg from CBER, Dr Jay Siegel from Centocor, Professor Don Rubin from Harvard University, Dr Gregory Campbell from CBER, Dr Stacy Lindborg from Eli Lilly, Dr Robert O’Neill from CDER, and Professor Ralph D’Agostino, Boston University. Our task when we set up this panel was to give this group the opportunity to summarize, from their perspective, what they have heard, and also think about what is next. Speaking on behalf of the Planning Committee, we are interested in questions, as well as comments from the audience, as related to the use of Bayesian methods as a tool, particularly in the context of the critical path initiative, reduce the time for review and approval of new public health products.
Cited by 5 works. doi:10.1191/1740774505cn107oa